UNITY Biotechnology to Participate in Upcoming Investor Conferences
Rhea-AI Summary
UNITY Biotechnology (NASDAQ: UBX), a company focused on developing therapeutics for age-related diseases, has announced its participation in two upcoming investor conferences. The company will provide corporate updates and engage in one-on-one meetings at these events:
1. H.C. Wainwright 4th Annual Ophthalmology Virtual Conference on August 15, 2024, at 7:00 a.m. ET (virtual presentation)
2. H.C. Wainwright 26th Annual Global Investment Conference on September 9, 2024, at 7:00 a.m. ET in New York, NY
Live webcasts of both presentations will be available through UNITY's website, with archived replays accessible for 90 days after the events. These conferences provide UNITY with opportunities to showcase its progress in developing treatments to slow, halt, or reverse diseases of aging.
Positive
- None.
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, UBX gained 2.08%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
SAN FRANCISCO, Aug. 12, 2024 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, today announced that members of its senior management team will provide a corporate update and participate in one-on-one meetings at the following investor conferences.
H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
Presentation Date and Time: Thursday, August 15, 2024 at 7:00 a.m. ET
Location: Virtual
Webcast Link: Webcast
H.C. Wainwright 26th Annual Global Investment Conference
Presentation Date and Time: Monday, September 9, 2024 at 7:00 a.m. ET
Location: New York, NY
Webcast Link: Webcast
The live webcasts of the presentations will be accessible through the “Investors & Media” section of our website, www.unitybiotechnology.com, under “Events & Presentations.” Archived replays will be available for 90 days following the events.
About UBX1325
UBX1325 is an investigational compound being studied in retinal diseases, including DME, and is not approved for any use in any country. UBX1325 is a potent small molecule inhibitor of Bcl-xL, a member of the BCL-2 family of apoptosis regulating proteins. UBX1325 is designed to inhibit the function of proteins that senescent cells rely on for survival. The Phase 2 BEHOLD study in patients with DME demonstrated that a single injection of UBX1325 resulted in a statistically significant and clinically meaningful improvement in mean BCVA through 48 weeks compared to sham treatment. In preclinical studies, UNITY has demonstrated that targeting Bcl-xL with UBX1325 preferentially eliminated senescent cells from diseased tissue while sparing cells in healthy tissue. UNITY’s goal with UBX1325 is to transformationally improve real-world outcomes for patients with retinal disease.
About UNITY
UNITY is developing a new class of therapeutics to slow, halt, or reverse diseases of aging. UNITY’s current focus is on creating medicines to selectively eliminate or modulate senescent cells and thereby provide transformative benefit in age-related ophthalmologic and neurologic diseases. More information is available at www.unitybiotechnology.com or follow us on X and LinkedIn.
Media Contact
Inizio Evoke Comms
Katherine Smith
Katherine.Smith@inizioevoke.com
Investor Contact
LifeSci Advisors, LLC
Joyce Allaire
jallaire@lifesciadvisors.com
FAQ
When is UNITY Biotechnology (UBX) presenting at the H.C. Wainwright Ophthalmology Virtual Conference?
Where can investors access the webcast for UNITY Biotechnology's (UBX) presentations?
How long will the archived replays of UNITY Biotechnology's (UBX) conference presentations be available?
What is the focus of UNITY Biotechnology's (UBX) therapeutic development?
